Cardiol Therapeutics (NASDAQ:CRDL) Trading Up 2.7% – Here’s What Happened

Posted by Francis Steltz on Sep 18th, 2026

Cardiol Therapeutics Inc. (NASDAQ:CRDL – Get Free Report)’s share price traded up 2.7% during trading on Wednesday . The company traded as high as $1.90 and last traded at $1.90. Approximately 1,579,710 shares traded hands during trading, an increase of 1% from the average daily volume of 1,558,781 shares. The stock had previously closed at $1.85.

Analysts Set New Price Targets

CRDL has been the subject of a number of research analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cardiol Therapeutics in a research note on Wednesday, June 24th. Canaccord Genuity Group upped their price objective on shares of Cardiol Therapeutics from $8.00 to $10.00 and gave the stock a “buy” rating in a report on Monday, August 17th. HC Wainwright restated a “buy” rating on shares of Cardiol Therapeutics in a report on Tuesday, July 14th. Wall Street Zen raised shares of Cardiol Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. Finally, B. Riley Financial began coverage on shares of Cardiol Therapeutics in a research report on Wednesday, August 26th. They set a “buy” rating and a $11.00 price target on the stock. Three analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $10.00.

Get Our Latest Report on CRDL

Cardiol Therapeutics Trading Up 5.6%

The company has a market cap of $228.29 million, a PE ratio of -7.86 and a beta of 0.79. The stock has a 50 day moving average price of $1.64 and a 200 day moving average price of $1.35.

Cardiol Therapeutics (NASDAQ:CRDL – Get Free Report) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.09) by $0.05. Equities analysts expect that Cardiol Therapeutics Inc. will post -0.19 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. Concurrent Investment Advisors LLC purchased a new stake in Cardiol Therapeutics in the second quarter worth about $27,000. Royal Bank of Canada increased its position in Cardiol Therapeutics by 62.3% during the 1st quarter. Royal Bank of Canada now owns 21,648 shares of the company’s stock valued at $29,000 after buying an additional 8,306 shares in the last quarter. PVG Asset Management Corp increased its position in Cardiol Therapeutics by 10.3% during the 1st quarter. PVG Asset Management Corp now owns 107,165 shares of the company’s stock valued at $145,000 after buying an additional 10,000 shares in the last quarter. Renaissance Technologies LLC purchased a new position in Cardiol Therapeutics during the first quarter valued at $310,000. Finally, Integrity Alliance LLC. purchased a new position in Cardiol Therapeutics during the fourth quarter valued at $416,000. 12.49% of the stock is currently owned by institutional investors.

Cardiol Therapeutics Company Profile

(Get Free Report)

Cardiol Therapeutics Inc is a clinical-stage biotechnology company focused on developing anti-inflammatory therapies for diseases of the heart. The company’s research centers on the role of inflammation in cardiovascular conditions, including myocarditis and pericarditis, for which treatment options remain limited.

Cardiol’s lead investigational product is CardiolRx, an oral pharmaceutical formulation of cannabidiol designed for use in cardiovascular medicine. The product is being evaluated in clinical research involving acute myocarditis and recurrent pericarditis.